HVTN 054

A Phase I Dose-Escalation Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiclade, Multivalent Recombinant Adenoviral Vector HIV Vaccine, VRC-HIVADV014-00-VP, in Healthy, HIV-1 Uninfected Adult Participants Who Have Low Titers of Pre-Existing Ad5 Neutralizing Antibodies

Trial Details:

I Completed
HVTN, National Institute of Allergy and Infectious Diseases (NIAID), Vaccine Research Center (VRC) April 01, 2005
VRC-HIVADV014-00-VP Ad5 Gag-Pol Env A/B/C
VRC-HIVADV014-00-VP Viral Vector - Adeno
USA 48